Biophytis is leading the development of new classes of therapeutics that make the body more resilient to stress to provide people with age-related and genetic diseases an enhanced quality of life.
Using reverse pharmacology and our proprietary library containing hundreds of bioactive molecules naturally produced by plants in response to stress, we have identified compounds from a unique collection of natural plant substances. After testing their efficacy on cellular and animal models of age-related diseases, we have determined their mechanism of action. The information we collect through this process makes it possible for us to improve (i) the structure of the compounds by medicinal chemistry (structure-activity relationship studies) and (ii) the compounds’ metabolic and pharmacokinetic characteristics in order to increase their effectiveness.
Biophytis has decided to concentrate its research efforts on the degeneration of the muscle and the degeneration of the retina, pathologies for which the selected molecules seem to have the most potential. Sarcopenia (age-related muscular dystrophy) and AMD (age-related macular degeneration) have been given priority as the major causes of disability in the over-65 age group and no treatment is currently available for them. Since 2017, Biophytis has also invested in adapting its programmes to genetic degenerative diseases: Duchenne muscular dystrophy and Stargardt disease.
https://www.biophytis.com/en/pipeline/
